Kontafarma China Holdings Limited provided group earnings guidance for the year ended December 31, 2022. The board of directors of the company informed the shareholders of the company and potential investors of the Group that, based on the latest unaudited consolidated management accounts of the Group for the year ended 31 December 2022 and the latest information available to the Board, the Group is expected to record a consolidated net loss in the region of approximately HKD 43.2 million to HKD 64.8 million for the fiscal year 2022, compared to the consolidated net loss of approximately HKD 4.6 million for the year ended 31 December 2021.